Company Overview

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing proprietary drug delivery technologies and specialty biologics. The company operates primarily within the biopharmaceutical and drug delivery industries, with a business model centered on enabling more efficient administration of injectable biologic therapies. Halozyme is best known for its ENHANZE® drug delivery technology, which facilitates the subcutaneous delivery of biologics that are traditionally administered intravenously.

The company’s primary revenue drivers are licensing agreements, collaboration revenues, and royalties generated from partnered products that incorporate ENHANZE®. Halozyme serves global pharmaceutical and biotechnology companies as its core customer segment, positioning itself as a platform technology provider rather than a traditional fully integrated biopharma company. Founded in 1998, Halozyme initially pursued oncology and enzyme-based therapeutics before strategically pivoting in the mid-2000s to focus on drug delivery, a transition that ultimately established its current licensing- and royalty-driven business model.

Business Operations

Halozyme operates through two core business segments: ENHANZE® Drug Delivery Technology and Proprietary Product Development. The ENHANZE® segment is the dominant contributor to revenue, generating income through upfront payments, milestone payments, and recurring royalties from global collaboration partners. These partners integrate Halozyme’s recombinant human hyaluronidase enzyme (rHuPH20) into their biologic therapies to enable subcutaneous administration.

The company’s proprietary product development efforts are more limited and historically have included oncology-focused assets, though Halozyme has largely deemphasized internal drug commercialization in favor of partnering. Halozyme conducts operations primarily in the United States, with clinical, regulatory, and commercial activities tied to partner-led global programs. The company maintains full ownership and control of its ENHANZE® intellectual property and has entered into multiple long-term licensing agreements with large pharmaceutical companies.

Strategic Position & Investments

Halozyme’s strategic direction emphasizes expanding the adoption of ENHANZE® across additional biologic therapies and therapeutic areas, thereby increasing long-term royalty streams. Growth initiatives include signing new collaboration agreements, supporting partners’ regulatory approvals, and extending ENHANZE® into high-value indications such as oncology, immunology, and rare diseases.

Major strategic transactions have included the divestiture of non-core assets and a disciplined capital allocation approach focused on share repurchases rather than large-scale acquisitions. Notable subsidiaries include Halozyme, Inc., which holds the company’s intellectual property and operating assets. Halozyme is actively involved in enabling next-generation biologic formulations but does not directly invest in emerging modalities such as gene therapy beyond its role as a delivery enabler.

Geographic Footprint

Halozyme is headquartered in San Diego, California, which serves as its primary operational and administrative center. While the company’s direct operations are largely U.S.-based, its commercial influence is global through partnerships with multinational pharmaceutical companies.

The company’s technology is incorporated into products marketed across North America, Europe, and parts of Asia-Pacific, depending on partner approvals. Halozyme’s international presence is primarily indirect, relying on collaborators for manufacturing, regulatory filings, and commercialization in global markets.

Leadership & Governance

Halozyme is led by an executive team with deep experience in biotechnology, pharmaceutical partnering, and capital markets. The leadership emphasizes a disciplined, shareholder-focused strategy centered on high-margin licensing revenues, operational efficiency, and return of capital.

Key executives include:

• Helen Torley, MB ChB, MRCP – President and Chief Executive Officer
• Jonathan Lim – Chief Financial Officer
• Michael W. Vytla, PhD – Chief Business Officer
• Dr. Steven Y. Chang – Vice President, Research
• Andrea Lyons – Chief Legal Officer and Corporate Secretary

The board and executive leadership collectively emphasize long-term value creation through strategic partnerships, intellectual property stewardship, and prudent financial management.